Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study.
Adolescent
Adult
Afghanistan
/ epidemiology
Antitubercular Agents
/ therapeutic use
Female
Fluoroquinolones
/ therapeutic use
Humans
Male
Pregnancy
Retrospective Studies
Rifampin
/ therapeutic use
Treatment Outcome
Tuberculosis, Multidrug-Resistant
/ drug therapy
World Health Organization
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
06
2020
accepted:
31
07
2020
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Afghanistan is affected by one of the world's longest protracted armed conflicts, frequent natural disasters, disease outbreaks and large population movements and it suffers from a high burden of tuberculosis (TB), including rifampicin-resistant TB (RR-TB). The study shows Médecins Sans Frontières' experiences with care for patients with RR-TB in Kandahar Province. We describe the uptake of RR-TB treatment, how World Health Organisation criteria for the choice between the short and an individualized regimen were implemented, and treatment outcomes. This is a retrospective cohort analysis of routinely collected data from RR-TB patients enrolled in care from 2016 until 2019. Descriptive analysis was performed to present characteristics of patients and treatment outcomes. Multivariable Cox analysis was performed to identify risk factors for having an unfavourable treatment outcome. Out of 146 enrolled RR-TB patients, 112 (76.7%) started treatment: 41 (36.6%) and 71 (63.4%) with the short and individualized treatment regimen, respectively. Of 82 with results for fluoroquinolone susceptibility, 39 (47.6%) had fluoroquinolone-resistant TB. Seven patients with initially fluoroquinolone-resistant TB and three pregnant women started the short regimen and 18 patients eligible for the short regimen started the injectable-free individualized regimen. Overall, six-month smear and culture conversion were 98.7% and 97.1%, respectively; treatment success was 70.1%. Known initial fluoroquinolone resistance (aHR 3.77, 95%CI:1.53-9.27) but not choice of regimen predicted having an unfavourable outcome. Even though criteria for the choice of treatment regimen were not applied strictly, we have achieved acceptable outcomes in this cohort. To expand RR-TB care, treatment regimens should fit provision at primary health care level and take patient preferences into account.
Identifiants
pubmed: 32822375
doi: 10.1371/journal.pone.0237787
pii: PONE-D-20-18479
pmc: PMC7446914
doi:
Substances chimiques
Antitubercular Agents
0
Fluoroquinolones
0
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237787Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2013 Dec;57(12):1676-84
pubmed: 24065321
Soc Sci Med. 2011 Oct;73(7):1003-13
pubmed: 21862194
Arch Dis Child. 2019 Jul;104(7):622-628
pubmed: 30523172
Pediatr Infect Dis J. 2013 Feb;32(2):115-9
pubmed: 22926210
Int J Tuberc Lung Dis. 2014 May;18(5):515-9
pubmed: 24903785
Bull World Health Organ. 2017 Aug 1;95(8):584-593
pubmed: 28804170
J Infect Public Health. 2019 Nov - Dec;12(6):809-815
pubmed: 31056438
Int J Tuberc Lung Dis. 2014 May;18(5):520-7
pubmed: 24903786
Clin Infect Dis. 2020 Feb 14;70(5):907-916
pubmed: 30944927
Confl Health. 2014 Dec 01;8:25
pubmed: 25904975
Int J Tuberc Lung Dis. 2009 Aug;13(8):976-81
pubmed: 19723377
Pediatrics. 2002 May;109(5):765-71
pubmed: 11986434
Int Health. 2015 May;7(3):169-75
pubmed: 25492948
Int J Tuberc Lung Dis. 2016 Dec;20(12):1671-1676
pubmed: 27931345
PLoS One. 2017 May 31;12(5):e0178053
pubmed: 28562675
BMC Pregnancy Childbirth. 2018 Jun 18;18(1):246
pubmed: 29914439
Rev Saude Publica. 2019 Sep 23;53:77
pubmed: 31553380
BMC Infect Dis. 2014 Jun 17;14:333
pubmed: 24938738
Confl Health. 2014 Feb 07;8(1):3
pubmed: 24507446
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331041
Glob Health Sci Pract. 2018 Oct 4;6(3):594-602
pubmed: 30287534
Int J Tuberc Lung Dis. 2015 Sep;19(9):1109-14, i-ii
pubmed: 26260834
BMC Health Serv Res. 2014 Feb 21;14:81
pubmed: 24559177
Eur Respir J. 2016 Nov;48(5):1503-1507
pubmed: 27587544
Int J Tuberc Lung Dis. 2019 Jun 1;23(6):714-719
pubmed: 31315704
Clin Infect Dis. 2019 Nov 29;:
pubmed: 31781758
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331033
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 31862767
Int J Tuberc Lung Dis. 2018 May 1;22(5):3-6
pubmed: 29665947
Clin Infect Dis. 2020 Jul 11;71(2):415-418
pubmed: 31676905
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049176